Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: Association with stage and grade in vivo and link with response to rapamycin treatment in vitro

Journal of Cancer Research and Clinical Oncology

Volumn 135, Issue 7, 2009, Pages 933-941

  Darb Esfahani, Silvia ^a   Faggad, Areeg ^a   Noske, Aurelia ^a   Weichert, Wilko ^a   Buckendahl, Ann Christin ^a   Müller, Berit ^a   Budczies, Jan ^a   Röske, Annika ^a   Dietel, Manfred ^a   Denkert, Carsten ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Endometrial adenocarcinoma; PI3 K AKT mTOR pathway; Rapamycin

Indexed keywords

CARRIER PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHOPROTEIN; PROTEIN KINASE B; PROTEIN P 4EBP1; RAPAMYCIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; EIF4EBP1 PROTEIN, HUMAN; PROTEIN KINASE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CELL DIFFERENTIATION; CELL GROWTH; ENDOMETRIUM CANCER; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TREATMENT RESPONSE; ADENOCARCINOMA; ENDOMETRIUM TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PHOSPHORYLATION; PROGNOSIS; TREATMENT OUTCOME; TUMOR CELL CULTURE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PHOSPHOPROTEINS; PHOSPHORYLATION; PROGNOSIS; PROTEIN KINASES; SIROLIMUS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 66949159435     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-008-0529-5     Document Type: Article

References (28)

1. G Armengol F Rojo J Castellvi 2007 4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications Cancer Res 67 7551 7555 10.1158/0008-5472.CAN-07-0881
2. VL Bae-Jump C Zhou PA Gehrig YE Whang JF Boggess 2006 Rapamycin inhibits hTERT telomerase mRNA expression, independent of cell cycle arrest Gynecol Oncol 100 487 494 10.1016/j.ygyno.2005.08.053
3. JR Bayascas DR Alessi 2005 Regulation of Akt/PKB Ser473 phosphorylation Mol Cell 18 143 145 10.1016/j.molcel.2005.03.020
4. J Castellvi A Garcia F Rojo C Ruiz-Marcellan A Gil J Baselga S Ramon y Cajal 2006 Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer Cancer 107 1801 1811 10.1002/cncr.22195
5. LM Chow SJ Baker 2006 PTEN function in normal and neoplastic growth Cancer Lett 241 184 196 10.1016/j.canlet.2005.11.042
6. B Culjkovic I Topisirovic KL Borden 2007 Controlling gene expression through RNA regulons: the role of the eukaryotic translation initiation factor eIF4E Cell Cycle 6 65 69 (Pubitemid 46173883)
7. L Dudkin MB Dilling PJ Cheshire 2001 Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition Clin Cancer Res 7 1758 1764 (Pubitemid 32708646)
8. JB Easton PJ Houghton 2006 mTOR and cancer therapy Oncogene 25 6436 6446 10.1038/sj.onc.1209886
9. A Gadducci S Cosio AR Genazzani 2006 Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies Crit Rev Oncol Hematol 58 242 256 10.1016/j.critrevonc.2005.11.002
10. N Gao DC Flynn Z Zhang 2004 G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3 K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells Am J Physiol Cell Physiol 287 C281 C291 10.1152/ajpcell.00422.2003
11. JL Hecht GL Mutter 2006 Molecular and pathologic aspects of endometrial carcinogenesis J Clin Oncol 24 4783 4791 10.1200/JCO.2006.06.7173
12. B Herberger H Puhalla M Lehnert 2007 Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinoma Clin Cancer Res 13 4795 4799 10.1158/1078-0432.CCR-07-0738
13. A Jemal R Siegel E Ward T Murray J Xu MJ Thun 2007 Cancer statistics, 2007 CA Cancer J Clin 57 43 66 (Pubitemid 46148091)
14. Y Kanamori J Kigawa H Itamochi 2001 Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma Clin Cancer Res 7 892 895 (Pubitemid 32708726)
15. CL Kremer RR Klein J Mendelson 2006 Expression of mTOR signaling pathway markers in prostate cancer progression Prostate 66 1203 1212 10.1002/pros.20410
16. BT Nave M Ouwens DJ Withers DR Alessi PR Shepherd 1999 Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation Biochem J 344 427 431 10.1042/0264-6021:3440427
17. K Oda D Stokoe Y Taketani F McCormick 2005 High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma Cancer Res 65 10669 10673 10.1158/0008-5472.CAN-05-2620
18. D Pectasides E Pectasides T Economopoulos 2007 Systemic therapy in metastatic or recurrent endometrial cancer Cancer Treat Rev 33 177 190 10.1016/j.ctrv.2006.10.007
19. J Prat 2004 Prognostic parameters of endometrial carcinoma Hum Pathol 35 649 662 10.1016/j.humpath.2004.02.007
20. F Rojo L Najera J Lirola 2007 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis Clin Cancer Res 13 81 89 10.1158/1078-0432.CCR-06-1560
21. EK Rowinsky 2004 Targeting the molecular target of rapamycin (mTOR) Curr Opin Oncol 16 564 575 10.1097/01.cco.0000143964.74936.d1
22. DM Sabatini 2006 mTOR and cancer: insights into a complex relationship Nat Rev Cancer 6 729 734 10.1038/nrc1974
23. E Steiner O Eicher J Sagemuller 2003 Multivariate independent prognostic factors in endometrial carcinoma: a clinicopathologic study in 181 patients: 10 years experience at the Department of Obstetrics and Gynecology of the Mainz University Int J Gynecol Cancer 13 197 203 10.1046/j.1525-1438.2003.13021.x
24. Tavassoli FA, Devilee P (2003) World Health Organization classification of tumours: tumours of the breast and the female genital organs. IARC Press, Lyon
25. O Treeck B Wackwitz U Haus O Ortmann 2006 Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells Gynecol Oncol 102 292 299 10.1016/j.ygyno.2005.12.019
26. S Wullschleger R Loewith MN Hall 2006 TOR signaling in growth and metabolism Cell 124 471 484 10.1016/j.cell.2006.01.016
27. C Zhou PA Gehrig YE Whang JF Boggess 2003 Rapamycin inhibits telomerase activity by decreasing the hTERT mRNA level in endometrial cancer cells Mol Cancer Ther 2 789 795
28. X Zhou M Tan V Stone Hawthorne 2004 Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers Clin Cancer Res 10 6779 6788 10.1158/1078-0432. CCR-04-0112